FDA Officially Designates Tandem’s Control-IQ Class II
Executive Summary
After more than three years of treating the Tandem Diabetes Care Control-IQ Technology system as moderate-risk class II, the US FDA has made the designation official. The classification will also apply to future similar devices.
You may also be interested in...
Dexcom G6 Finally Gets Official Classification
After nearly four years of treating the Dexcom glucose monitoring system as moderate-risk class II, the US FDA made the designation official.
Market Intel: Glucose Monitor Market Set To Explode As Patients Access Better Devices
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
FDA Takes Another Swing At Banning Electrical Shock Devices
The US FDA wants to ban devices that use an electrical shock to stop aggressive behavior. The agency attempted to ban the devices in 2020 but failed after it was challenged in court.